Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chugai Pharma hPTHR1 compound 2a
- Development stage
- Unknown
- Lead developer
- Chugai Pharmaceutical
01
Overview
Chugai Pharma hPTHR1 compound 2a: sourced facts only. name: "Compound 2a, bearing a bicyclic aromatic ring, was identified as a novel hPTHR1 agonist during hit to lead modification." [PMID:38273777]; target: "Compound 2a, bearing a bicyclic aromatic ring, was identified as a novel hPTHR1 agonist during hit to lead modification." [PMID:38273777]; developer: "Chugai Pharmaceutical Co., Ltd., Research Division, 216 Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa, Japan, 244-0003." [PMID:38273777]
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on Chugai Pharma hPTHR1 compound 2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chugai Pharma hPTHR1 compound 2a.